Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.94 USD | -3.61% |
|
-9.57% | -88.21% |
05-14 | Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform | MT |
05-10 | Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.21% | 106M | |
+15.85% | 121B | |
+20.03% | 113B | |
+17.47% | 26.02B | |
-25.18% | 19.39B | |
-19.51% | 15.91B | |
-19.24% | 15.09B | |
-46.87% | 15.06B | |
+61.94% | 14.93B | |
+6.31% | 13.85B |
- Stock Market
- Equities
- RAPT Stock
- News RAPT Therapeutics, Inc.
- JPMorgan Downgrades RAPT Therapeutics to Neutral From Overweight, Price Target is $15